Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone.
PTH is an anabolic agent used to treat osteoporosis, but its mechanisms of action are unclear. This study elucidated target cells and mechanisms for anabolic actions of PTH in mice during bone growth. Mice with c-fos ablation are osteopetrotic and lack an anabolic response to PTH. In this study, there were no alterations in PTH-regulated osteoblast differentiation or proliferation in vitro in cells from c-fos -/- mice compared with +/+; hence, the impact of osteoclastic cells was further investigated. A novel transplant model was used to rescue the osteopetrotic defect of c-fos ablation. Vertebral bodies (vossicles) from c-fos -/- and +/+ mice were implanted into athymic hosts, and the c-fos -/- osteoclast defect was rescued. PTH treatment to vossicle-bearing mice increased 5-bromo-2'-deoxyuridine (BrdU) positivity in the bone marrow and increased bone area regardless of the vossicle genotype. To inhibit recruitment of osteoclast precursors to wild-type vossicles, stromal derived factor-1 signaling was blocked, which blunted the PTH anabolic response. Treating mice with osteoprotegerin to inhibit osteoclast differentiation also blocked the anabolic action of PTH. In contrast, using c-src mutant mice with a late osteoclast differentiation defect did not hinder the anabolic action, suggesting key target cells reside in the intermediately differentiated osteoclast population in the bone marrow. These results indicate that c-fos in osteoblasts is not critical for PTH action but that cells of the osteoclast lineage are intermediate targets for the anabolic action of PTH.
Koh
Amy J
AJ
Department of Periodontics and Oral Medicine, School of Dentistry, Room 3343, University of Michigan, 1011 North University Avenue, Ann Arbor, Michigan 48109-1078, USA.
Demiralp
Burak
B
Neiva
Kathleen G
KG
Hooten
Joanna
J
Nohutcu
Rahime M
RM
Shim
Hyunsuk
H
Datta
Nabanita S
NS
Taichman
Russell S
RS
McCauley
Laurie K
LK
D045930:Anabolic Agents / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis; D015152:Blotting, Northern; D001846:Bone Development / Q000187:drug effects*; D016025:Bone Transplantation; D001842:Bone and Bones / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D019070:Cell Lineage; D002478:Cells, Cultured; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D008819:Mice, Nude; D010010:Osteoclasts / Q000166:cytology / Q000502:physiology*; D010022:Osteopetrosis / Q000209:etiology / Q000473:pathology / Q000601:surgery; D010281:Parathyroid Hormone / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D016760:Proto-Oncogene Proteins c-fos / Q000172:deficiency; D013131:Spine; D013194:Staining and Labeling
D045930:Anabolic Agents; D018797:Cell Cycle Proteins; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D016760:Proto-Oncogene Proteins c-fos; D002118:Calcium